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Supporting Material 
 
Materials and Methods 
 
Construction, expression and purification of hADAR2-D 
The expression vector encoding hADAR2-D was constructed by PCR amplification from 
a hADAR2 cDNA template and ligated into the vector YEpTOP2PGAL1 as described 
previously (S1). This construct encodes an N-terminal 10-histidine tag, a TEV protease 
recognition sequence, and residues 299-701 of hADAR2. The protein was expressed in S. 
cerevisiae and purified using nickel chelating, heparin ion exchange, and gel filtration 
chromatography, as described for other N-terminal truncations of hADAR2 (S1). The 
purified protein was dialyzed into buffer (20 mM Tris-HCl pH 8.0, 100 mM NaCl, 1 mM 
2-mercaptoethanol, and 5% glycerol) and concentrated to 10 mg/ml. 
 
RNA preparation and deamination assays 
Duplex RNA encoding sense and antisense sequences of the chloramphenicol acetyl 
transferase gene (CAT duplex) was internally labeled during in vitro transcription with α-
32P ATP, and gel purified as previously described (S2). The in vitro editing assay was 
performed by incubating purified protein and CAT duplex RNA under conditions 
described previously (S1), with concentrations described in the legend to Figure S1.  
 
Crystallization and Data Collection 
hADAR2-D was crystallized by vapor diffusion at 21°C by mixing 2 µl of protein 
solution with 2 µl of well solution (0.1 M Bis-Tris pH 6.8, 0.2 M (NH4)2SO4, 24% PEG 
3350, and 7.5% glycerol). After 10 days, crystals were mounted in nylon loops and   2 
cryocooled by plunging into liquid nitrogen. All data were collected at 100 K using a 
Rigaku R-AXIS IV image plate detector mounted on a rotating anode source. Data were 
integrated and scaled using the programs DENZO and SCALEPACK (S3). The crystals 
belonged to space group P212121 and contained two molecules in the asymmetric unit. 
 
Multiple Isomorphous replacement, model building and refinement 
Isomorphous heavy atom derivatives were prepared by soaking crystals at room 
temperature in well solutions containing either 0.5 mM thimerosal (C9H9HgO2SNa) or 
0.5 mM mercury acetate (Hg[C2H3O2]2) for 1 hour, or 20 mM sodium tungstate 
(Na2WO4) for 3 hours. Data were collected and processed as above, and scaled against 
the native data set. Heavy atom sites were located by inspection of Patterson functions. 
Most crystallographic computing used programs from the CCP4 suite (S4). Phases from 
the thimerosal and mercury acetate derivatives were calculated using SOLVE (S5), and 
used to locate two tungstate clusters (each containing the same arrangement of twelve 
tungsten atoms) in a difference Fourier map (Figure S2). MIR phases from the three 
derivatives were calculated using SOLVE (figure of merit 0.75) and generated an easily 
interpretable electron density map after density modification by solvent flattening (42% 
solvent) using the program RESOLVE (S6). An initial model was built by RESOLVE 
(S6), and manually completed using the XFIT program in the XTALVIEW software 
package (S7). The model was refined using REFMAC5 (S8), using refinement parameters 
for the IP6 ligand that were generated using the SKETCHER program in CCP4 (S4). It is 
possible that some of the solvent molecules currently assigned as water are other species, 
such as sodium ions, although this is not apparent from the electron density or inspection   3 
of coordination geometry. Figures were generated using the PyMOL molecular graphics 
system (S9) and Figure 3B was initially made using the program LIGPLOT (S10) then 
modified using CHEMDRAW (CambridgeSoft, Cambridge, MA). 
 
Yeast Strains and Extract preparation 
  hADAR2 was expressed in the strain BCY123 as described previously (S1). The 
IPK1 gene in this strain was replaced with the kanamycin resistance gene 
(ipk1Δ::KanMX) using a PCR-based gene targeting method (S11). The knockout was 
confirmed by the ability to grow in the presence of the antibiotic G418, and PCR of the 
genomic DNA. The new strain (BCY123-ipk1Δ) was also used to express hADAR2 as 
described above. Cells were harvested by centrifugation, resuspended in buffer (20 mM 
Tris-HCl pH 8.0, 100 mM NaCl, 20% glycerol and 1 mM 2-mercaptoethanol) and lysed 
by three consecutive passes through a French pressure cell at 20,000 psi. The lysate was 
centrifuged at 100,000 x g for 1 hour at 4°C. The supernatant (S100 extract) was stored in 
aliquots at -80°C until use in the editing assays. 
For the ADAT1 activity assays, the yeast strain BY4743 (wild-type; S12) and 
strains with the same genetic background but having the IPK1 gene or the KCS1 gene 
replaced with KanMX (ipk1Δ::KanMX, kcs1Δ::KanMX), were obtained from Research 
Genetics (Huntsville, AL). The strains were grown in YPD, harvested by centrifugation, 
and S100 extract was prepared as described above.  
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RNA preparation 
  For the in vitro editing assays, RNA substrates were prepared using the splint 
ligation method of Moore and Sharp (S13). The R/G 27-mer RNA used for the hADAR2 
editing assays was prepared as described (S14). The tRNAs were chemically synthesized 
in two halves. For labeling A34, the two RNAs spanned residues 1-33 (the 5’ half) and 
34-76 (the 3’ half); for labeling A37, the two RNAs spanned residues 1-36 (the 5’ half) 
and 37-76 (the 3’ half). The 3’ halves were phosphorylated (at either A34 or A37) with 
32P using polynucleotide kinase, and annealed, along with their respective 5’ partner, to a 
DNA “splint” of complementary sequence to the 76-nucleotide tRNA
ala. The RNAs were 
then ligated using T4 DNA ligase, the DNA splint was digested with RQ1 DNase 
(Promega, Madison, WI), and the RNA purified on a 12% denaturing polyacrylamide gel.  
  To assay editing in vivo, total RNA was prepared from the S100 extract by 
extraction with Trizol
TM reagent (Invitrogen) as per the manufacturers instructions. The 
RNA was precipitated with isopropanol and treated with the restriction enzyme Cac8I 
(New England BioLabs, Ipswich, MA), followed by RQ1 DNase (Promega) to digest any 
remaining DNA. The RNA was extracted with phenol, precipitated with ethanol, and 
quantified. tRNA
ala was amplified by RT-PCR, using primers specific for the tRNA
ala 
sequence and the PCR product was sequenced (see below). 
  RT-PCR was used to measure amounts of the ADAT1 and hADAR2 mRNAs 
expressed in the ipk1Δ strains relative to those messages produced in the wild-type strain. 
Total RNA was prepared as described above, except after RQ1 DNase treatment, the 
restriction digest step was omitted and the RNA was further purified using an RNeasy
TM 
kit (Qiagen, Valencia, CA) according to the manufacturers instructions. The RNA was   5 
reverse transcribed with Superscript
TM II reverse transcriptase (Invitrogen, Carlsbad, CA) 
using an oligo-dT primer. A region of the cDNA (947-1175 of the ADAT1 gene, 2050-
2324 of hADAR2 gene) was amplified by quantitative real-time PCR using a Roche 
Light Cycler with SYBR-Green fluorescent NTPs and gene specific primers. RT-PCR 
product amounts were normalized to that of a housekeeping gene (GAPDH) for 
quantitation. 
 
Editing assays 
  hADAR2 concentrations in extracts prepared from BCY123 or BCY-ipk1Δ were 
quantified by western blotting. The blot was probed with a penta-His primary antibody 
(Qiagen) and alkaline phosphatase conjugated anti-mouse secondary antibody (Sigma-
Aldrich, St. Louis, MO). Protein bands were detected using a fluorescent alkaline 
phosphatase ECF substrate (Amersham, Piscataway, NJ). The blot was scanned on a 
PhosphorImager, and the hADAR2 bands were quantified after generating a standard 
concentration curve of known amounts of a purified protein (the histidine tagged R2D 
truncation of hADAR2, S1). Editing of the R/G site RNA by hADAR2 in vitro was 
performed as previously described (S1). Briefly, 5 nM RNA was reacted with increasing 
concentrations of hADAR2 present in yeast extracts (final concentrations of hADAR2 are 
indicated in Fig. 4A) for 1 hour at 30°C. 
  Yeast extracts for editing tRNA in vitro were prepared as described above and 
quantified by Bradford assay. 5 nM of A34 or A37 labeled tRNA
ala was reacted with  
10
-3, 10
-2, 0.1, 2.9, 5.8 µg/µl total protein for 1 hour at 30°C. IP6 or IS6 (concentrations 
noted in the legend to Fig. 4A; Sigma-Aldrich) were incubated with 0.1 µg/µl extract for   6 
15 min at 30°C before adding 5 nM A37 labeled tRNA
ala. Reactions were completed as 
described above. 
To observe editing in vivo, total RNA was prepared from the yeast S100 extracts 
(see above) and the tRNA was amplified by RT-PCR using gene specific primers. The 
PCR product was sequenced using a 
32P-labeled primer that hybridized to the non-
template strand, and the Sequenase
TM PCR product sequencing kit (USB, Cleveland, 
OH.) according to the manufacturers instructions. The sequencing products were 
separated on an 8% denaturing polyacrylamide gel. The gel was dried and exposed to a 
PhosphorImager plate overnight. 
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Figure S1. (A) Domain structure of hADAR2 and the catalytic domain construct used in 
this study. Striped rectangles, dsRBMs; filled rectangle, catalytic domain. (B) In vitro 
deamination assay. 10 nM 
32P-A-labeled dsRNA was incubated with 100 nM of full-
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length hADAR2 or hADAR2-D for 1 hour. Reacted dsRNA was treated with P1 
nuclease, the resulting 5’-NMPs separated by thin-layer chromatography, and the plate 
exposed to a phosphorimage screen. Lane 1, no protein control; Lane 2, hADAR2 treated 
dsRNA; Lane 3, hADAR2-D treated RNA. Origin, 5’AMP and 5’IMP spots are 
indicated.  
 
Figure S2. The electron density of a tungstate cluster containing 12 tungsten atoms 
observed in the heavy atom derivative (the tungsten atoms are modeled as grey spheres). 
The cluster is bound to a positively charged region on the surface near the active site of 
hADAR2-D (8 Å from the zinc, pink sphere). The density was calculated using (Ftungstate-
Fnative) with protein phases computed from the thimerosal derivative, and is contoured at 
4σ. 
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Figure S3. (A) 2Fobs-Fcalc electron density map (contoured at 1σ, purple or 9σ, white) of 
the region surrounding the active site Zn. (B) 2Fobs-Fcalc electron density map (purple) 
contoured at 1σ and Fobs-Fcalc electron density map contoured at 3σ (cyan) calculated 
prior to inclusion of IP6 in the model. 
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Figure S4. Another view of the ribbon model of hADAR2-D. The protein is rotated 90° 
about the vertical axis from Fig. 1B of the main text. IP6 is shown as sticks. The active 
site zinc atom is obscured by β11. The color scheme is the same as Figure 1B of the main 
text. Ends of the disordered segment (residues 462-473) are indicated with asterisks (the 
beginning of the disordered region is obcured by β10).  
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Figure S5. (A) The zinc coordinating environment of cytidine deaminase (S15). Zinc ion 
(magenta sphere), nucleophilic water (blue sphere), zinc coordinating bonds (grey dashed 
lines), hydrogen bonds (pink dashed lines). The thiolate of C129 forms hydrogen bonds 
with the backbone NH groups of residues H131 and C132 located at the N-terminus of 
the helix. These interactions are expected to reduce the negative character of the C129 
thiolate, and thus increase the positive potential of the zinc ion. This may modulate 
catalysis by lowering the pKa of the coordinated water molecule that attacks the substrate 
C4 center of cytidine (S16). C132 is not within hydrogen bonding distance to any other 
residues. (B) The zinc-coordinating environment of hADAR2. A 64-residue loop 
separates C451 from C516, and the N-terminus of helix α5 is therefore less extended than 
in cytidine deaminase. The thiolate of C451 only forms one hydrogen bond with an 
amide NH (of C516). A consequent increase in water molecule pKa may be offset by a 
hydrogen-bonding interaction seen between the thiolate of C516 and the side chain of 
K483. The equivalent C132 of cytidine deaminase does not participate in hydrogen 
bonding interactions, whereas K483 is invariant in ADARs.  
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Table S1. Crystallographic Data  
  Native  Thimerosal  Mercury 
Acetate 
Sodium 
Tungstate 
a (Å) 
b (Å) 
c (Å) 
52.2 
121.4 
127.5 
52.3 
121.7 
127.6 
52.6 
121.8 
127.8 
52.1 
120.8 
127.4 
Resolution (Å) 
 
20-1.7 
(1.76-1.7) 
20-2.7 
(2.8-2.7) 
20-2.7 
(2.8-2.7) 
20-2.6 
(2.69-2.6) 
# total reflections  388,243  228,747  54,141  120,441 
# unique reflections  82,849  22,696  20,785  25,089 
Completeness (%)  92.3  
(62.5) 
100  
(100) 
89.7  
(87.9) 
99.5  
(99.8) 
Mosaicity (˚)  0.5  0.6  0.7  0.7 
I/σ(I)  35.2  
(5.0) 
21.2  
(9.3) 
10.9  
(4.6) 
8.7  
(2.9) 
Rmerge
a 
 
3.9 
(25.9) 
13.4 
(26.9) 
9.2 
(19.4) 
11.2 
(26.8) 
Numbers in parenthesis are for the high-resolution bin 
aRmerge = 100xΣ|I-<I>|/ΣI 
 
Table S2. Refinement statistics 
Rcryst (%)
a  17.4 
Rfree (%)
b  20.7 
# Protein residues modeled  741 
# Solvent molecules  670 
RMSD bonds (Å)  0.015 
RMSD angles (˚)  1.554 
φ, ψ Most favored (%)  92.7 
φ, ψ Additional Allowed (%)  6.4 
<B> Overall (Å
2) 
<B> Main Chain (Å
2) 
<B> Side Chains (Å
2) 
<B> Water (Å
2) 
<B> IP6 (Å
2) 
19.9 
17.8 
20.2 
28.0 
14.6 
aRcryst = 100xΣ||Fobs|-k|Fcalc||/Σ|Fobs| 
bRfree = The Rfactor against 5% of the data removed prior to refinement 
Stereochemistry was analyzed using PROCHECK (S17) 
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Figure S6. Alignments for regions surrounding the residues that coordinate IP6 in 
hADAR2 are shown, with hADAR2 numbering indicated in blue. IP6 coordinating 
residues for backbone interactions (red capitals) and side chain interactions (bold, red 
capitals) are indicated. The alignment was prepared with the entire catalytic domain as 
input, using GCG software (Wisconsin Package Version 10.3, Accelrys Inc., San Diego, 
CA). Pileup, using default parameters, was used to align the following sequences 
(accession number; amino acids aligned, start-end): ADAR1, human (NM_001111; 833-
1226), mouse (AF052506; 756-1152), rat (U18942; 779-1175), Xenopus laevis (U88065; 
879-1270), pufferfish (AAF69764; 790-1194), zebrafish (NM_131596; 952-1382); 
ADAR2, human (NM_001112; 317-701), rat (NP_037026; 317-711), mouse (AF403106; 
317-701), chicken (AF403119; 318-701), pufferfish (AF533143; 309-694), zebrafish 
(AF403113; 305-689), D. melanogaster (AF208535; 252-632), C. elegans (AF051275; 
113-495); the entire open-reading frame for ADAT1, human (AF125188), mouse 
(NM_013925), chicken (NM_001012779), Xenopus tropicalis (CR762003), D. 
melanogaster (AF192530). This multiple sequence alignment was used as input to the 
program HmmerBuild to create a profile hidden Markov model (HMM) of the consensus 
(global alignment setting). The HMM file was then used with the program HmmerAlign 
to add the following to the alignment S. cerevisiae ADAT1, (AJ007297; 11-401), C. 
elegans adr-1c (AY150815; 617-964) and human ADAR3 (AF034837; 355-739). The 
alignment was optimized by selective manual manipulation using the program Seaview 
(S18). Manual manipulation was guided by alignments of the subgroups alone. Sequences 
diverge considerably in the region surrounding K483; the alignment shown was chosen 
because the conserved lysine of various subfamilies is aligned with K483 of hADAR2.   14 
 
Figure S7. To rule out an ADAT1 requirement for IP7, which is downstream of IP6 in the 
inositol polyphosphate synthesis pathway, we assayed editing of A37 of tRNA
ala by 
ADAT1 in extracts prepared from yeast unable to produce IP7. The KCS1 gene product 
phosphorylates IP6 to form IP7. ADAT1 from a kcs1Δ strain edits A37 with equal 
efficiency as ADAT1 from a wild-type strain, suggesting, along with the data from the 
ipk1Δ strain, that IP6 is the required factor for editing activity. Left panel, TLC assay of 
tRNAala-A37 editing by ADAT1 in wild-type extracts or kcs1∆ extracts. Right panel, 
quantitation of inosine product as a function of wild-type or kcs1∆ extract concentration. 
Dashed line, ADAT1 activity in kcs1∆ extract; solid line, activity in wild-type extract. 
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Figure S8. Electrospray mass spectrometry analysis of ADAR2-D and IP6. Upper panel, 
molecular mass spectrum of native ADAR2-D. The sample was purified as described 
above, except Triton X-100 was not included in the lysis buffer. After purification, the 
protein was dialyzed against water and any remaining buffer was exchanged with water   16 
using a Micron-10 centrifugal concentrator (Millipore, Billerica, MA). 5% acetonitrile 
(final concentration) was added to the sample before (+) ion electrospray data were 
collected in the 600-1400 m/z mass range. The spray voltage was 2.8 kV and cone 
voltage was 40 eV. The data were processed into a “molecular mass spectrum” using 
MAXENT software (Micromass, Beverly, MA). The ADAR2-D (44998.1 Da, observed; 
44997.1 Da, calculated) peak and ADAR2-D peaks containing IP6 (660 Da MW, i.e. 
neutral molecule) are labeled red. The 45071.9 Da and 45730.2 Da peaks are likely an 
oxidized cysteine/β-mecaptoethanol (β-ME) derivative (in the crystal structure, the thiol 
group of C634 exists in 2 conformations on the protein surface, and appears to be 
oxidized). In addition, the 45137.2 peak may contain zinc (65.4 Da). Lower panel, mass 
spectrum of inositol hexakisphosphate (dipotassium salt) purchased from Sigma (St. 
Louis, MO). The compound was dissolved in water (final concentration 10 mM) diluted 
with acetonitrile and triethylamine (final concentrations 50% and 3%, respectively) and 
analyzed by electrospray in (-) ion mode. The peaks corresponding to the -1 and -2 
charge states as well as a potassium salt of IP6 are labeled red.  IP3 and IP5 
contaminants/hydrolysis products are also labeled. 
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